PRISMA 2020 Checklist

Location where item is reported	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Title
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Abstract
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Section 1, Introduction
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Section 1, final paragraphs and Research Questions 1–3
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Sections 2.3–2.4; Supplementary Tables S3–S4
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Section 2.1 (Scopus and Web of Science; search date 25 July 2025)
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Section 2.1; Table 1
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Section 2.3 (two reviewers; independent two-stage screening; decisions agreed through discussion)
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Section 2.4 (structured extraction framework; two reviewers; decisions agreed through discussion)
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Section 2.4 (conceptual-role classification of subjective/self-report variables; assessment-content domain grouping)
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Section 2.4 (location, objective,

Location where item is reported	Item #	Checklist item	Location where item is reported
			duration, sample, setting, design, methods, tools, comparison conditions, reported outcomes)
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Section 2.4: formal risk-of-bias/methodological-quality appraisal was not undertaken; rationale provided
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Not applicable to the primary methodological synthesis; Section 2.4 notes that effect estimates were recorded where relevant but not pooled
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Sections 2.3–2.4 (eligibility criteria, modality classification, conceptual-role classification, assessment-content domain coding, publication-level modality combinations, and participant-alignment rules)
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Not applicable; the review used descriptive/narrative synthesis and did not transform effect data
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Section 2.4; Table 2; Supplementary Tables S4 and S6; Figures 6–7
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the	Section 2.4

Location where item is reported	Item #	Checklist item	Location where item is reported
		model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	(narrative/descriptive synthesis; frequencies and proportions; no meta-analysis, with rationale)
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	Not applicable; no effect-size meta-analysis or subgroup/meta-regression analysis was conducted
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Not applicable; no sensitivity analyses were conducted
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	Not applicable to the descriptive methodological synthesis; no effect-synthesis reporting-bias assessment was conducted
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	Not applicable; no certainty-of-evidence grading was undertaken
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Section 3.2; Figure 6 (PRISMA flow diagram)
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Section 3.2; Supplementary Table S3 (record-level screening/eligibility log)
Study characteristics	17	Cite each included study and present its characteristics.	Table 2; Supplementary Table S6; References 31–49
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Not applicable; no formal risk-of-bias appraisal was undertaken (Section

Location where item is reported	Item #	Checklist item	Location where item is reported
			2.4)
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Supplementary Table S6 presents study-level characteristics and reported findings; effect estimates were not a target of the methodological synthesis
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Sections 3.2–3.6; Table 2; Supplementary Table S6; risk of bias not assessed
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Sections 3.3–3.6; Figure 7 (assessment-content domain frequencies, publication-level modality combinations, and participant-aligned multimethod assessment); Supplementary Table S4.
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Not applicable; no heterogeneity analyses of effect estimates were conducted
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Not applicable; no sensitivity analyses were conducted
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Not applicable; no reporting-bias assessment was conducted
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Not applicable; no certainty-of-evidence assessment was conducted
DISCUSSION			

Location where item is reported	Item #	Checklist item	Location where item is reported
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Sections 4.1–4.5
	23b	Discuss any limitations of the evidence included in the review.	Section 4.6
	23c	Discuss any limitations of the review processes used.	Section 4.6
	23d	Discuss implications of the results for practice, policy, and future research.	Sections 4.5–4.6; Section 5, Conclusion
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Not registered.
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	No formal review protocol was prepared.
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	Not applicable; the review was not registered and no formal review protocol was prepared.
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Funding statement in Buildings back matter
Competing interests	26	Declare any competing interests of review authors.	Conflicts of Interest statement in Buildings back matter
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Data Availability Statement; Supplementary Materials (Tables S1–S6)

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71.
This work is licensed under CC BY 4.0. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/